J-147

J-147 is one of the most promising preclinical brain-aging compounds and one of the least proven things a person could actually buy, and both statements come from the same fact. The science is strong and none of the aging data is in humans. What separates it from riskier research chemicals is a benign downside, which is why it earns a 6.0 rather than a neutral score. The mechanism is real and specific, the aging-reversal data is coherent across cognition, gene expression, and multiple organs, and the injury work has independent-lab support (Jin et al. 2024). But no human efficacy result has been released, and the new stroke trial (NCT07430917) will not fill that gap for aging. Treat it as a compound worth a careful personal test if you accept the evidence gap, not a proven intervention.

✅ Best for: Self-directed longevity experimenters who want the strongest preclinical brain-aging candidate available and who accept that its aging benefit is unproven in humans. People building a neuro-focused stack alongside compounds like rapamycin who treat J-147 as a calculated bet, not a staple. Researchers and analysts who want the clearest example of a target-identified geroprotector to benchmark the field. Readers who can verify a vendor's certificate of analysis and are comfortable with a gray-market research chemical rather than an approved product.

❌ Avoid if: You want a proven human benefit, since no efficacy data has been released and the aging case is entirely preclinical. You cannot verify supply, because gray-market powder carries no purity guarantee, no dose verification, and no recourse if a vial is wrong. You would weight-scale a mouse dose to your own body, which has no pharmacokinetic basis in people. You are pregnant, on complex medication, or want an evidence-backed cognitive option today, in which case a supplement like methylene-blue or lions-mane has human data J-147 lacks.